138 related articles for article (PubMed ID: 36787661)
21. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
22. Excision of residual masses of metastatic germ cell tumours after chemotherapy: the role of extraperitoneal surgical approaches.
Christmas TJ; Doherty AP; Rustin GJ; Seckl MJ; Newlands ES
Br J Urol; 1998 Feb; 81(2):301-8. PubMed ID: 9488076
[TBL] [Abstract][Full Text] [Related]
23. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
24. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours.
Harding MJ; Brown IL; MacPherson SG; Turner MA; Kaye SB
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1689-94. PubMed ID: 2561098
[TBL] [Abstract][Full Text] [Related]
25. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
26. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
27. Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours.
Horvath LG; McCaughan BC; Stockle M; Boyer MJ
Intern Med J; 2002 Mar; 32(3):79-83. PubMed ID: 11885847
[TBL] [Abstract][Full Text] [Related]
28. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.
Notarfrancesco M; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Thalmann G; Beyer J
Swiss Med Wkly; 2023 Apr; 153():40053. PubMed ID: 37080191
[TBL] [Abstract][Full Text] [Related]
29. Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor.
King JM; Althouse S; Cary C; Masterson T; Foster RS; Ashkar R; Hanna NH; Einhorn LH; Adra N
J Urol; 2022 Sep; 208(3):641-649. PubMed ID: 35674780
[TBL] [Abstract][Full Text] [Related]
30. Long-term clinical outcome in patients with stage-I nonseminomatous germ cell cancer. A critical review of own treatment modalities in a retrospective study.
Seseke S; Bierwirth S; Strauss A; Ringert RH; Seseke F
Int Braz J Urol; 2008; 34(6):715-22; discussion 723-4. PubMed ID: 19111076
[TBL] [Abstract][Full Text] [Related]
31. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis.
Culine S; Theodore C; Court BH; Perrin JL; Droz JP
Br J Urol; 1997 Feb; 79(2):258-62. PubMed ID: 9052479
[TBL] [Abstract][Full Text] [Related]
33. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
[TBL] [Abstract][Full Text] [Related]
34. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
35. Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.
Pierorazio PM; Cheaib JG; Patel HD; Gupta M; Sharma R; Zhang A; Tema G; Bass EB
J Urol; 2021 Feb; 205(2):370-382. PubMed ID: 32915080
[TBL] [Abstract][Full Text] [Related]
36. Results of postchemotherapy adjunctive retroperitoneal lymph node dissection in non-seminomatous germ cell cancer patients.
Goepel M; Recker F; Otto T; Krege S; Rübben H
Urol Int; 1996; 57(4):209-12. PubMed ID: 8961487
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy for stage I non-seminomatous testicular cancer.
Abratt RP; Pontin AR; Barnes RD; Reddi BV
S Afr Med J; 1994 Sep; 84(9):605-7. PubMed ID: 7530863
[TBL] [Abstract][Full Text] [Related]
39. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
[TBL] [Abstract][Full Text] [Related]
40. [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].
Matveev VB; Volkova MI; Cherniev VA; Figurin KM; Mitin AV
Urologiia; 2010; (3):41-7. PubMed ID: 20734877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
